If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering whether these symptoms signal a deeper problem. Decades of pharmacovigilance have established that certain medications can slow gastric emptying, and GLP-1 receptor agonists like Ozempic are now part of that recognized landscape. This page reviews the risk factors and monitoring considerations for gastroparesis in Ozempic users.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for chronic weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have been documented in clinical trials. In a pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests. The gastrointestinal adverse reactions associated with Ozempic, including nausea, vomiting, dyspepsia, and gastroesophageal reflux disease, overlap with symptoms of gastroparesis. Specifically, the label reports dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (placebo 0%, Ozempic 0.5 mg 2.7%, Ozempic 1 mg 1.1%), flatulence (placebo 0.8%, Ozempic 0.5 mg 0.4%, Ozempic 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, Ozempic 0.5 mg 1.9%, Ozempic 1 mg 1.5%), and gastritis (placebo 0.8%, Ozempic 0.5 mg 0.8%, Ozempic 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that gastrointestinal symptoms are dose-related and occur more frequently with higher doses.
Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying through activation of GLP-1 receptors on vagal afferent neurons and enteric neurons, leading to reduced antral contractions and increased pyloric tone. This pharmacodynamic effect is intended to promote satiety and reduce postprandial glucose excursions. However, in susceptible individuals, this delay in gastric emptying can become pathological, resulting in gastroparesis. The label does not explicitly list gastroparesis as an adverse reaction, but the reported gastrointestinal adverse reactions—particularly nausea, vomiting, dyspepsia, and gastroesophageal reflux disease—are consistent with gastroparesis symptomatology. The temporal relationship between Ozempic initiation and symptom onset is often during dose escalation, as noted in the label: the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This suggests that the risk of developing gastroparesis-like symptoms may be highest when the dose is increased.
Regarding risk anchors, the adequacy of warnings about Ozempic and gastroparesis is a key consideration. The label includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic, and that caution is advised in patients with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis. The gastrointestinal adverse reactions are listed, but the term "gastroparesis" is absent. This omission may affect the adequacy of warnings, as patients and healthcare providers may not associate Ozempic use with the risk of developing a chronic gastric motility disorder. For affected patients, settlement-related considerations would involve documenting the timeline between Ozempic exposure and the onset of gastroparesis symptoms, as well as the severity and duration of harm. The label data indicate that gastrointestinal adverse reactions are most common during dose escalation, but symptoms may persist or worsen with continued use. Patients who develop gastroparesis after starting Ozempic may need to demonstrate that the drug caused or contributed to their condition, which requires careful medical documentation of symptom onset, diagnostic testing, and exclusion of other causes. In summary, the evidence from the Ozempic label shows a clear dose-related increase in gastrointestinal adverse reactions that overlap with gastroparesis symptoms. The mechanistic pathway through delayed gastric emptying supports a plausible link between Ozempic and gastroparesis. However, the label does not explicitly warn about gastroparesis, which may be a critical factor in assessing the adequacy of warnings for affected patients. Settlement considerations will depend on individual case details, including the timing of exposure, symptom development, and the presence of other risk factors.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying. This can lead to symptoms like nausea, vomiting, and bloating, which overlap with gastroparesis. Clinical data show dose-related gastrointestinal adverse reactions, and the label does not explicitly warn about gastroparesis, raising concerns about adequate warnings.
Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy or breath tests, and evidence that symptoms began after starting Ozempic, especially during dose escalation. Other causes must be excluded, and the severity and duration of harm are considered.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.